deCODE Receives California Clinical Laborato...( REYKJAVIK February 19 /- deCODE g...),Health

REYKJAVIK, February 19 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced that it has received a clinical laboratory license from the State of California. The quality and scale of deCODE's in-house, CLIA-registered genotyping laboratory underpins deCODE's global leadership in the discovery of variations in the sequence of the human genome conferring risk of common diseases. The same staff and facility also process deCODE's DNA-based reference laboratory tests for gauging individual risk of major public health challenges ranging from heart attack to breast cancer, as well as the company's pioneering deCODEme(TM) scans, the world's first personal genome analysis and focused disease area scans. With this license, California residents can now benefit from the unrivalled quality of deCODE products for understanding risk and, working with their physicians, empowering the prevention of common diseases.

"We believe that understanding genetic risk factors for the common diseases such as heart attack, stroke, type 2 diabetes and common cancers will soon become a standard part of modern healthcare. This information enables individuals to take more control of their health, and is driving the transition from a healthcare system based upon treating diseases once they occur to one focused on disease prevention and early detection. deCODE is unique in that we are the leaders both in the discovery of genetic risk factors for common diseases and in bringing to market the reference laboratory tests and direct-to-consumer scans that enable individuals and their physicians to put these discoveries to work to better protect their health. Our competitors outsource the science, the DNA-analysis, or both. But for us this is the real foundation of personalized medicine, and we are committed to delivering only the best validated
'/>"/>